Biotech week ahead, Feb. 3

Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing.
Pfizer Inc. PFE 0.49% reported disappointing fourth-quarter earnings and Amgen, Inc. AMGN 4.47% guided 2020 below consensus, while Eli Lilly And Co LLY 2.11% managed to outperform expectations.
The week continued to see coronavirus-related spikes, with Cleveland BioLabs, Inc. CBLI 34.29%, NanoViricides, Inc. NNVC 40.15%, Vir Biotechnology, Inc. VIR 13.17% and Vaccinex, Inc. VCNX 8% among the stocks riding on the momentum.
Acceleron Pharma Inc XLRN 5.19% was one of the standout gainers of the week, thanks to a positive midstage clinical readout.
The much-anticipated FDA verdict on Aimmune Therapeutics Inc’s AIMT 2.91% peanut allergy drug Palforzia came through in the week, with the regulatory agency greenlighting the drug.

Turning ahead to the unfolding week, the following are key catalysts that could create a ripple in the biotech space.

Conferences

• 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy: Feb. 5-7 in Paris, France
• The European Association for Hemophilia and Allied Disorders, or EAHAD, 2020 Congress: Feb. 5-7 in Hague, Netherlands
• ASCO-SITC Clinical Immuno-Oncology Symposium: Feb. 6-8 in Orlando, Florida
• Angiogenesis, Exudation, and Degeneration 2020: Feb. 8 in Miami, Florida

Clinical Readouts

Forty Seven Inc FTSV 7.11% is due to present at the ASCO-SITC Symposium Phase 1b data for magrolimab + avelumab in ovarian cancer.
Jounce Therapeutics Inc JNCE 0.47% will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors. (Feb. 6)
Catalyst Biosciences Inc CBIO 5.46% is scheduled to present at the EAHAD Congress Phase 2b data for dalcinonacog alfa in hemophilia B. (Feb. 7)
Kodiak Sciences Inc KOD 2.19% is due to present at the Angiogenesis, Exudation, and Degeneration 2020with Phase 1b data for KSI-301 in diabetic macular edema (Feb. 8)
Adverum Biotechnologies Inc ADVM 5% will present at the Angiogenesis, Exudation, and Degeneration 2020 with Phase 1 data for ADVM-022 in wet age-related macula degeneration. (Feb. 8)

Earnings

Monday

• Catalent Inc CTLT 1.39% (before the market open)
• Taro Pharmaceutical Industries Ltd. TARO 0.64% (after the close)

Tuesday

• Zimmer Biomet Holdings Inc ZBH 2.19% (before the market open)
• Haemonetics Corporation HAE 1.84% (before the market open)
• BIO-TECHNE Corp TECH 1.42% (before the market open)
• Neurocrine Biosciences, Inc. NBIX 1.41% (after the close)
• Gilead Sciences, Inc. GILD 1.3% (after the close)
• Qiagen NV QGEN 0.66% (after the close)

Wednesday

• Merck & Co., Inc. MRK 1.21% (before the market open)
• Boston Scientific Corporation BSX 3.59% (before the market open)
• Arrowhead Pharmaceuticals Inc ARWR 0.94% (after the close)
• Cardiovascular Systems Inc CSII 3.86% (after the close)
• Misonix Inc MSON 5.06% (after the close)
• SurModics, Inc. SRDX 1.3% (after the close)

Thursday

• ABIOMED, Inc. ABMD 0.3% (before the market open)
• Bristol-Myers Squibb Co BMY 1.35% (before the market open)
• Alnylam Pharmaceuticals, Inc. ALNY 0.57% (before the market open)
• Regeneron Pharmaceuticals Inc REGN 0.52% (before the market open)
• Twist Bioscience Corp TWST 3.28% (after the close)
• Anavex Life Sciences Corp AVXL 1.04% (after the close)
• Pacific Biosciences of California PACB 0.43% (after the close)
• Enanta Pharmaceuticals Inc ENTA 1.94% (after the close)
• Myriad Genetics, Inc. MYGN 2.23% (after the close)
• Seattle Genetics, Inc. SGEN 1.35% (after the close)
• Natus Medical Inc NTUS 1.57% (after the close)
• LeMaitre Vascular Inc LMAT 0.85% (after the close)
• Ligand Pharmaceuticals Inc. LGND 2.23% (after the close)

Friday

• AbbVie Inc (NYSE: ABBV (before the market open)
• Meridian Bioscience, Inc. (NASDAQ: VIVO (before the market open)

IPOs

Beam Therapeutics plans to offer 6.25 million shares in an IPO, with the offering expected to be priced between $15 and $17. The company, which is engaged in developing therapies based on single-base gene editing, has applied for listing its shares on the Nasdaq under the ticker symbol “BEAM.”
Contract research organization PPD is planning a 60-million-share IPO to be priced in the range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol “PPD.”
https://www.benzinga.com/general/biotech/20/02/15229115/the-week-ahead-in-biotech-merck-bristol-myers-earnings-conference-presentations-in-focus